chr2-227052367-G-C
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000092.5(COL4A4):āc.2906C>Gā(p.Ser969Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000323 in 1,613,292 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ). Synonymous variant affecting the same amino acid position (i.e. S969S) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000092.5 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL4A4 | NM_000092.5 | c.2906C>G | p.Ser969Ter | stop_gained | 32/48 | ENST00000396625.5 | NP_000083.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL4A4 | ENST00000396625.5 | c.2906C>G | p.Ser969Ter | stop_gained | 32/48 | 5 | NM_000092.5 | ENSP00000379866 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000105 AC: 16AN: 152126Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000681 AC: 17AN: 249564Hom.: 0 AF XY: 0.0000739 AC XY: 10AN XY: 135394
GnomAD4 exome AF: 0.000346 AC: 505AN: 1461166Hom.: 0 Cov.: 30 AF XY: 0.000338 AC XY: 246AN XY: 727002
GnomAD4 genome AF: 0.000105 AC: 16AN: 152126Hom.: 0 Cov.: 32 AF XY: 0.000121 AC XY: 9AN XY: 74308
ClinVar
Submissions by phenotype
Autosomal recessive Alport syndrome Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 15, 2023 | Variant summary: COL4A4 c.2906C>G (p.Ser969X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been associated with Alport Syndrome in HGMD. The variant allele was found at a frequency of 6.8e-05 in 249564 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in COL4A4 causing Alport Syndrome, Autosomal Recessive (6.8e-05 vs 0.0016), allowing no conclusion about variant significance. c.2906C>G has been reported in the literature in multiple individuals affected with Alport Syndrome, Autosomal Recessive (Dagher_2002, Storey_2013, etc). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. 12 ClinVar submitters have submitted clinical-significance assessments for this variant to ClinVar after 2014. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Nov 18, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Pathogenic, criteria provided, single submitter | research | Cavalleri Lab, Royal College of Surgeons in Ireland | May 27, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Dec 18, 2018 | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. - |
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics, Royal Melbourne Hospital | Mar 30, 2023 | This sequence change creates a premature termination codon at position 969 in exon 32 (of 48) of COL4A4 (p.Ser969*). It is expected to result in an absent or disrupted protein product in a gene where loss of function is a well-established mechanism of disease (PVS1). The variant is present in a large population cohort at a frequency of 0.006%, which is consistent with a recessive condition (rs35138315, 18/280956 alleles, 0 homozygotes in gnomAD v2.1.1 - PM2_Supporting). Furthermore, it has been reported as homozygous and compound heterozygous with a second pathogenic allele in multiple cases with Alport syndrome (PMID: 24052634 - PM3_Strong). Based on the classification scheme RMH ACMG Guidelines v1.2.1, this variant is classified as PATHOGENIC. Following criteria are met: PVS1, PM3_Strong, PM2_Supporting. - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 22, 2024 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 34662886, 34758253, 29431110, 30406062, 25525159, 30647093, 31980526, 32723786, 35649421, 24052634, 26346198, 12325029, 36939041) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 12, 2024 | This sequence change creates a premature translational stop signal (p.Ser969*) in the COL4A4 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in COL4A4 are known to be pathogenic (PMID: 21196518, 24854265, 25307543). This variant is present in population databases (rs35138315, gnomAD 0.01%). This premature translational stop signal has been observed in individuals with Alport syndrome (PMID: 12325029, 24052634). ClinVar contains an entry for this variant (Variation ID: 449549). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | May 31, 2023 | - - |
Alport syndrome Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing | Sydney Genome Diagnostics, Children's Hospital Westmead | Apr 03, 2018 | This individual is heterozygous for a pathogenic variant c.2906C>G in the COL4A4 gene. This variant creates a premature stop codon p.(Ser969*) and may result in a null allele due to nonsense-mediated mRNA decay. This variant has been widely reported in patients with autosomal recessive Alport syndrome (Storey et al 2013 J Am Soc Nephrol 24: 1945-1954), and some patients with thin basement membrane nephropathy (Buzza et al 2003 Kidney Int 63:447-453). This variant has been reported in the gnomAD browser (http://gnomad.broadinstitute.org) with a low allele frequency of 0.006% (18/ 277, 194 alleles). This variant is considered to be pathogenic according to the ACMG guidelines. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
COL4A4-related disorder Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | May 26, 2022 | PVS1, PS1_Supporting, PM2, PM3 - |
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 20, 2024 | The COL4A4 c.2906C>G variant is predicted to result in premature protein termination (p.Ser969*). This variant has been reported to be pathogenic for autosomal recessive Alport syndrome (see for example, Dagher et al. 2002. PubMed ID: 12325029; Storey et al. 2013. PubMed ID: 24052634; Gast et al. 2015. PubMed ID: 26346198). In addition, this variant in the heterozygous (carrier) state has been reported in an individual with recurrent and persistent hematuria (Barton et al. 2022. PubMed ID: 35649421). This variant is reported in 0.012% of alleles in individuals of European (non-Finnish) descent in gnomAD. Nonsense variants in COL4A4 are expected to be pathogenic. This variant is interpreted as pathogenic for both autosomal dominant and autosomal recessive COL4A4-related conditions. - |
Chronic kidney disease Pathogenic:1
Pathogenic, criteria provided, single submitter | research | Cavalleri Lab, Royal College of Surgeons in Ireland | May 28, 2020 | PVS1, PS1 - |
Benign familial hematuria Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | Genomics England Pilot Project, Genomics England | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at